733 related articles for article (PubMed ID: 24229770)
1. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
[TBL] [Abstract][Full Text] [Related]
3. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
[TBL] [Abstract][Full Text] [Related]
4. Two-hour postload plasma glucose and pigment epithelium-derived factor levels are markers of coronary artery inflammation in type 2 diabetic patients.
Tahara N; Nitta Y; Bekki M; Tahara A; Maeda-Ogata S; Sugiyama Y; Honda A; Igata S; Nakamura T; Sun J; Kurata S; Fujimoto K; Abe T; Matsui T; Yamagishi SI; Fukumoto Y
J Nucl Cardiol; 2020 Aug; 27(4):1352-1364. PubMed ID: 31407236
[TBL] [Abstract][Full Text] [Related]
5. Effect of Liraglutide on Arterial Inflammation Assessed as [
Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
[TBL] [Abstract][Full Text] [Related]
6. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE).
Koyama H; Tanaka S; Monden M; Shoji T; Morioka T; Fukumoto S; Mori K; Emoto M; Shoji T; Fukui M; Fujii H; Nishizawa Y; Inaba M
Atherosclerosis; 2014 Jun; 234(2):329-34. PubMed ID: 24727234
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging.
Vucic E; Dickson SD; Calcagno C; Rudd JH; Moshier E; Hayashi K; Mounessa JS; Roytman M; Moon MJ; Lin J; Tsimikas S; Fisher EA; Nicolay K; Fuster V; Fayad ZA
JACC Cardiovasc Imaging; 2011 Oct; 4(10):1100-9. PubMed ID: 21999870
[TBL] [Abstract][Full Text] [Related]
9. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
[TBL] [Abstract][Full Text] [Related]
11. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
12. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events.
Figueroa AL; Abdelbaky A; Truong QA; Corsini E; MacNabb MH; Lavender ZR; Lawler MA; Grinspoon SK; Brady TJ; Nasir K; Hoffmann U; Tawakol A
JACC Cardiovasc Imaging; 2013 Dec; 6(12):1250-9. PubMed ID: 24269261
[TBL] [Abstract][Full Text] [Related]
13. The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial.
Boczar KE; Shin S; deKemp RA; Dowlatshahi D; Tavoosi A; Wiefels C; Liu P; Lochnan H; MacPherson PA; Chong AY; Torres C; Leung E; Tawakol A; Ahmadi A; Garrard L; Lefebvre C; Kelly C; MacPhee P; Tilokee E; Raggi P; Wells GA; Beanlands R
BMJ Open; 2023 Nov; 13(11):e074463. PubMed ID: 37949621
[TBL] [Abstract][Full Text] [Related]
14. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study.
Duivenvoorden R; Mani V; Woodward M; Kallend D; Suchankova G; Fuster V; Rudd JHF; Tawakol A; Farkouh ME; Fayad ZA
JACC Cardiovasc Imaging; 2013 Oct; 6(10):1087-1094. PubMed ID: 24135322
[TBL] [Abstract][Full Text] [Related]
15. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography.
Kim TN; Kim S; Yang SJ; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
Circ Cardiovasc Imaging; 2010 Mar; 3(2):142-8. PubMed ID: 20061516
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
17. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.
Kataoka Y; Shao M; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
Eur J Prev Cardiol; 2013 Apr; 20(2):209-17. PubMed ID: 22345692
[TBL] [Abstract][Full Text] [Related]
18. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
[TBL] [Abstract][Full Text] [Related]
19. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
Hong SJ; Kim ST; Kim TJ; Kim EO; Ahn CM; Park JH; Kim JS; Lee KM; Lim DS
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2655-65. PubMed ID: 21030718
[TBL] [Abstract][Full Text] [Related]
20. Coronary Plaque Morphology and the Anti-Inflammatory Impact of Atorvastatin: A Multicenter 18F-Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Study.
Singh P; Emami H; Subramanian S; Maurovich-Horvat P; Marincheva-Savcheva G; Medina HM; Abdelbaky A; Alon A; Shankar SS; Rudd JH; Fayad ZA; Hoffmann U; Tawakol A
Circ Cardiovasc Imaging; 2016 Dec; 9(12):e004195. PubMed ID: 27956407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
